Neural transplantation for Huntington's disease: Experimental rationale and recommendations for clinical trials
Identifieur interne : 002092 ( Main/Exploration ); précédent : 002091; suivant : 002093Neural transplantation for Huntington's disease: Experimental rationale and recommendations for clinical trials
Auteurs : Kathleen M. Shannon [États-Unis] ; Jeffrey H. Kordower [États-Unis]Source :
- Cell Transplantation [ 0963-6897 ] ; 1995.
Abstract
Huntington's disease (HD) is a neurodegenerative disorder affecting motor function, personality, and cognition. This paper reviews the experimental data that demonstrate the potential for transplantation of fetal striatum and trophic factor secreting cells to serve as innovative treatment strategies for HD. Transplantation strategies have been effective in replacing lost neurons or preventing the degeneration of neurons destined to die in both rodent and nonhuman primate models of HD. In this regard, a logical series of investigations has proven that grafts of fetal striatum survive, reinnervate the host, and restore function impaired following excitotoxic lesions of the striatum. Furthermore, transplants of cells genetically modified to secrete trophic factors such as nerve growth factor protect striatal neurons from degeneration due to excitotoxicity or mitochondrial dysfunction. Given the disabling and progressive nature of HD, coupled with the absence of any meaningful medical therapy, it is reasonable to consider clinical trials of neural transplantation for this disease. Fetal striatal implants will most likely be the first transplant strategy attempted for HD. This paper describes the variable parameters we believe to be critical for consideration for the design of clinical trials using fetal striatal implants for the treatment of HD.
Url:
DOI: 10.1016/0963-6897(95)02052-7
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Neural transplantation for Huntington's disease: Experimental rationale and recommendations for clinical trials</title><author><name sortKey="Shannon, Kathleen M" sort="Shannon, Kathleen M" uniqKey="Shannon K" first="Kathleen M." last="Shannon">Kathleen M. Shannon</name></author><author><name sortKey="Kordower, Jeffrey H" sort="Kordower, Jeffrey H" uniqKey="Kordower J" first="Jeffrey H." last="Kordower">Jeffrey H. Kordower</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D21D027FF7842860181FBD8A4E315B595959559</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/0963-6897(95)02052-7</idno><idno type="url">https://api.istex.fr/document/8D21D027FF7842860181FBD8A4E315B595959559/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002709</idno><idno type="wicri:Area/Main/Curation">002368</idno><idno type="wicri:Area/Main/Exploration">002092</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Neural transplantation for Huntington's disease: Experimental rationale and recommendations for clinical trials</title><author><name sortKey="Shannon, Kathleen M" sort="Shannon, Kathleen M" uniqKey="Shannon K" first="Kathleen M." last="Shannon">Kathleen M. Shannon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Research Center for Brain Repair and Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="Kordower, Jeffrey H" sort="Kordower, Jeffrey H" uniqKey="Kordower J" first="Jeffrey H." last="Kordower">Jeffrey H. Kordower</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Research Center for Brain Repair and Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Cell Transplantation</title><title level="j" type="abbrev">CTR</title><idno type="ISSN">0963-6897</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">5</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="339">339</biblScope><biblScope unit="page" to="352">352</biblScope></imprint><idno type="ISSN">0963-6897</idno></series><idno type="istex">8D21D027FF7842860181FBD8A4E315B595959559</idno><idno type="DOI">10.1016/0963-6897(95)02052-7</idno><idno type="PII">0963-6897(95)02052-7</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0963-6897</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Huntington's disease (HD) is a neurodegenerative disorder affecting motor function, personality, and cognition. This paper reviews the experimental data that demonstrate the potential for transplantation of fetal striatum and trophic factor secreting cells to serve as innovative treatment strategies for HD. Transplantation strategies have been effective in replacing lost neurons or preventing the degeneration of neurons destined to die in both rodent and nonhuman primate models of HD. In this regard, a logical series of investigations has proven that grafts of fetal striatum survive, reinnervate the host, and restore function impaired following excitotoxic lesions of the striatum. Furthermore, transplants of cells genetically modified to secrete trophic factors such as nerve growth factor protect striatal neurons from degeneration due to excitotoxicity or mitochondrial dysfunction. Given the disabling and progressive nature of HD, coupled with the absence of any meaningful medical therapy, it is reasonable to consider clinical trials of neural transplantation for this disease. Fetal striatal implants will most likely be the first transplant strategy attempted for HD. This paper describes the variable parameters we believe to be critical for consideration for the design of clinical trials using fetal striatal implants for the treatment of HD.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Shannon, Kathleen M" sort="Shannon, Kathleen M" uniqKey="Shannon K" first="Kathleen M." last="Shannon">Kathleen M. Shannon</name></region><name sortKey="Kordower, Jeffrey H" sort="Kordower, Jeffrey H" uniqKey="Kordower J" first="Jeffrey H." last="Kordower">Jeffrey H. Kordower</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002092 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002092 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8D21D027FF7842860181FBD8A4E315B595959559
|texte= Neural transplantation for Huntington's disease: Experimental rationale and recommendations for clinical trials
}}
| This area was generated with Dilib version V0.6.23. |  |